A One-Year, Randomized, Open-Label, Parallel-Arm, Phase 3 Long-Term Safety Trial, With Controlled Adjustment of Dose, of Multiple Doses of CG5503 PR and Oxycodone CR in Subjects With Chronic Pain.

Trial Profile

A One-Year, Randomized, Open-Label, Parallel-Arm, Phase 3 Long-Term Safety Trial, With Controlled Adjustment of Dose, of Multiple Doses of CG5503 PR and Oxycodone CR in Subjects With Chronic Pain.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Tapentadol (Primary) ; Oxycodone
  • Indications Back pain; Musculoskeletal pain; Osteoarthritis
  • Focus Adverse reactions; Registrational
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 19 Jul 2010 Results have been published in the journal, Pain Practice, according to a Pricara media release.
    • 10 Jun 2009 Results presented at the 10th Annual Congress of the European League Against Rheumatism, 10 Jun 2009.
    • 01 Apr 2009 Actual patient number (1122) added as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top